The Seroconversion Rate of Hepatitis A Virus Vaccination among Patients with Hepatitis B Virus-Related Chronic Liver Disease in Korea
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The aim of this study was to evaluate the seroconversion rate of a hepatitis A virus (HAV) vaccination in patients with hepatitis B virus (HBV)-related chronic liver disease (CLD). Methods: Analyses were conducted using clinical records from 94 patients with chronic HBV infection who were seronegative for IgG anti-HAV antibodies between September 2008 and June 2009. Two doses of an HAV vaccine were administered 24 weeks apart. A third vaccine dose was administered only for patients seronegative for anti-HAV antibodies at week 48. Results: The seroconversion rate of anti-HAV following the two-dose vaccination was 86.17%. The seroconversion rate of anti-HAV was not signifi cantly different according to age or status of liver disease. The rate was higher in female than in male patients. A third HAV vaccine dose was administered to 13 patients seronegative for anti-HAV after the two-dose regimen, and 84.62% of these patients showed seroconversion at week 72. Conclusions: HAV vaccination is effective in most Korean patients with HBV-related CLD, and it might be necessary to evaluate three-dose vaccination approach for non-responders to the conventional regimen to maximize the success of an HAV vaccination program.
Abstract
Background/Aims: The aim of this study was to evaluate the seroconversion rate of a hepatitis A virus (HAV) vaccination in patients with hepatitis B virus (HBV)-related chronic liver disease (CLD). Methods: Analyses were conducted using clinical records from 94 patients with chronic HBV infection who were seronegative for IgG anti-HAV antibodies between September 2008 and June 2009. Two doses of an HAV vaccine were administered 24 weeks apart. A third vaccine dose was administered only for patients seronegative for anti-HAV antibodies at week 48. Results: The seroconversion rate of anti-HAV following the two-dose vaccination was 86.17%. The seroconversion rate of anti-HAV was not signifi cantly different according to age or status of liver disease. The rate was higher in female than in male patients. A third HAV vaccine dose was administered to 13 patients seronegative for anti-HAV after the two-dose regimen, and 84.62% of these patients showed seroconversion at week 72. Conclusions: HAV vaccination is effective in most Korean patients with HBV-related CLD, and it might be necessary to evaluate three-dose vaccination approach for non-responders to the conventional regimen to maximize the success of an HAV vaccination program.
참고문헌 (23)
- Kang JH, "Changing hepatitis A epidemiology and the need for vaccination in Korea", Asian Pac J Allergy Immunol, 22, pp.237~242 (2004)
- Hyun Joo Song, "Emerging Need for Vaccination against Hepatitis A Virus in Patients with Chronic Liver Disease in Korea", Journal of Korean Medical Science, 22(2), pp.218~222 (2007), 대한의학회
- Moon HW, "Laboratory characteristics of recent hepatitis A in Korea: ongoing epidemiological shift", World J Gastroenterol, 16, pp.1115~1118 (2010)
- Jacobsen KH, "Declining hepatitis A seroprevalence: a global review and analysis", Epidemiol Infect, 132, pp.1005~1022 (2004)
- Tong MJ, "Clinical manifestations of hepatitis A: recent experience in a community teaching hospital", J Infect Dis, 171(Suppl 1), pp.S15~S18 (1995)
- Bell BP, "The diverse patterns of hepatitis A epidemiology in the United States: implications for vaccination strategies", J Infect Dis, 178, pp.1579~1584 (1998)
- Advisory Committee on Immunization Practices (ACIP), "Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)", MMWR Recomm Rep, 48(RR-12), pp.1~37 (1999)
- Bianco E, "Case fatality rate of acute viral hepatitis in Italy: 1995-2000. An update", Dig Liver Dis, 35, pp.404~408 (2003)
- Yao GB, "Clinical spectrum and natural history of viral hepatitis A in 1988 Shanghai epidemic, In Viral hepatitis and liver disease: proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease-- contemporary issues and future prospects", pp.76~78 (1991), Willams and Wilkins
- Hadler SC, "Global impact of hepatitis A virus infection-changing patterns, In Viral hepatitis and liver disease: proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease--contemporary issues and future prospects", pp.14~20 (1991), Willams and Wilkins
- Keeffe EB, "Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases", Am J Gastroenterol, 90, pp.201~205 (1995)
- Advisory Committee on Immunization Practices (ACIP), "Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)", MMWR Recomm Rep, 45(RR-15), pp.1~30 (1996)
- "Public health control of hepatitis A: memorandum from a WHO meeting", Bull World Health Organ, 73, pp.15~20 (1995)
- National Institutes of Health. National Institutes of Health Consensus Development Conference Statement, "Management of hepatitis C: 2002--June 10-12, 2002", Hepatology, 36, pp.S3~S20 (2002)
- Lee SD, "Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease", J Med Virol, 52, pp.215~218 (1997)
- Keeffe EB, "Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease", Hepatology, 27, pp.881~886 (1998)
- Dumot JA, "Immunogenicity of hepatitis A vaccine in decompensated liver disease", Am J Gastroenterol, 94, pp.1601~1604 (1999)
- Stark K, "Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients", J Infect Dis, 180, pp.2014~2017 (1999)
- Tsang SW, "Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection", Aliment Pharmacol Ther, 13, pp.1445~1449 (1999)
- Arguedas MR, "Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients", Hepatology, 34, pp.28~31 (2001)
- Reuman PD, "The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults", Vaccine, 15, pp.1157~1161 (1997)
- Van Damme P, "Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity", J Med Virol, 44, pp.435~441 (1994)
- Van Damme P, "Safety and immunogenicity of a high-potency inactivated hepatitis A vaccine", J Travel Med, 3, pp.83~90 (1996)